Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016;38(2):180-8.
doi: 10.3109/10641963.2015.1081213. Epub 2016 Jan 28.

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study

Alison Handley  1 , Eric Lloyd  2 , Andrew Roberts  2 , Bruce Barger  2
Affiliations
Clinical Trial

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study

Alison Handley et al. Clin Exp Hypertens. 2016.

Abstract

This 56-week phase 3, open-label, treat-to-target study, involving 2 consecutive, non-randomized cohorts, evaluated the safety and tolerability of azilsartan medoxomil (AZL-M) in essential hypertension (mean baseline blood pressure [BP] 152/100 mmHg). All subjects (n = 669) initiated AZL-M 40 mg QD, force-titrated to 80 mg QD at week 4, if tolerated. From week 8, subjects could receive additional medications, starting with chlorthalidone (CLD) 25 mg QD (Cohort 1) or hydrochlorothiazide (HCTZ) 12.5-25 mg QD (Cohort 2), if required, to reach BP targets. Adverse events (AEs) were reported in 75.9% of subjects overall in the two cohorts (73.8% Cohort 1, 78.5% Cohort 2). The most common AEs were dizziness (14.3%), headache (9.9%) and fatigue (7.2%). Transient serum creatinine elevations were more frequent with add-on CLD. Clinic systolic/diastolic BP (observed cases at week 56) decreased by 25.2/18.4 mmHg (Cohort 1) and 24.2/17.9 mmHg (Cohort 2). These results demonstrate that AZL-M is well tolerated over the long term and provides stable BP improvements when used in a treat-to-target BP approach with thiazide-type diuretics.

Keywords: Hypertension; angiotensin receptor blocker; azilsartan; chlorthalidone; diuretic; hydrochlorothiazide.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Subject disposition in Cohorts 1 (A) and 2 (B).
Figure 2.
Figure 2.
Mean sitting clinic SBP by study visit (observed cases). Data are mean ± SD. The dashed line at week 8 represents the first visit at which subjects in Cohort 1 could additionally have received CLD and subjects in Cohort 2 could additionally have received HCTZ.
Figure 3.
Figure 3.
Mean sitting clinic DBP by study visit (observed cases). Data are mean ± SD. The dashed line at week 8 represents the first visit at which subjects in Cohort 1 could additionally have received CLD and subjects in Cohort 2 could additionally have received HCTZ.
See this image and copyright information in PMC

References

    1. Edarbi (azilsartan medoxomil) tablets. U.S. prescribing information. Arbor Pharmaceuticals, LLC, Atlanta, GA, USA. Jul 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200796s006lbl.pdf [last accessed 13 Oct 2014]
    1. Edarbi (azilsartan medoxomil) tablets. Summary of product characteristics. Takeda Pharma A/S, Taastrup, Denmark. Oct 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info... [last accessed 13 Oct 2014]
    1. Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptor blocker. Clin Ther. 2011;33:1577–89. - PubMed
    1. De Caterina AR, Harper AR, Cuculi F. Critical evaluation of the efficacy and tolerability of azilsartan. Vasc Health Risk Manag. 2012;8:299–305. - PMC - PubMed
    1. Perry CM. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig. 2012;32:621–39. - PubMed

Publication types

LinkOut - more resources